Effects of glucose‐lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta‐analysis of randomized control trials
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Introduction: The effect of intensive glycaemic control alone or as part of a multifactorial intervention on cardiovascular and mortality outcomes is not fully understood. In addition, the interaction of duration of diabetes diagnosis on cardiovascular and mortality outcomes is unclear. Aim: To quantify the effect of intensive treatment (i.e. intensive glucose lowering either alone or as part of a multifactorial intervention) on non‐fatal myocardial infarction (MI), non‐fatal stroke, cardiovascular disease (CV) mortality and all‐cause mortality in patients with Type 2 diabetes. A secondary objective was to investigate the association between the treatment effect and trial‐level characteristics such as average age, duration of Type 2 diabetes, the percentage male and the baseline event rate. Methods: We searched MEDLINE, Embase and the Cochrane Central Register of Controlled Trials without language restrictions from inception to 13 May 2015. We included randomized controlled trials (RCT s) that evaluated intensive treatment in adult patients with Type 2 diabetes. The review was registered on PROSPERO (registration number 42014013860). We pooled rates across studies using random effects meta‐analysis and investigated study‐level covariate associations using Bayesian meta‐regression. Results: A total of 19 RCT s were included: 16 examined non‐fatal MI (n = 79 595), 14 non‐fatal stroke (n = 78 568), 18 cardiovascular mortality (n = 83 938) and 18 all‐cause mortality (n = 84 266). There was evidence to suggest that compared with standard care, intensive treatment reduced the risk of non‐fatal MI [risk ratio (RR) 0.90, 95% confidence interval (CI) 0.83–0.96], but not non‐fatal stroke (RR 0.96, 95% CI 0.86–1.07), CV mortality (RR 1.00, 95% CI 0.90–1.11) or all‐cause mortality (RR 1.00, 95% CI 0.94–1.06). Compared with standard care, multifactorial interventions alone reduced non‐fatal stroke (RR 0.53, 95% CI 0.32–0.0.87) but not non‐fatal MI (RR 0.66, 95% CI 0.38–1.03), CV mortality (RR 0.72, 95% CI 0.46–1.14) or all‐cause mortality (RR 0.82, 95% CI 0.64–1.05). There was no evidence to suggest that the effect of intensive treatment on cardiovascular and mortality outcomes was associated with mean age, mean duration of Type 2 diabetes and percentage of male patients across trials. There was evidence to suggest that the effectiveness of intensive treatment to reduce mortality outcomes increases as the baseline incidence of cardiovascular mortality [ratio of hazard = 0.82, 95% credible interval (CrI) 0.65–0.99] increased across trials, but not baseline incidence of non‐fatal MI, non‐fatal stroke and all‐cause mortality. Intensive glucose‐lowering and multifactorial interventions are predicted to have the desired beneficial effect of reducing CVD mortality in populations where the incidence rate is greater than about 6.3 CVD deaths per 1000 person‐years or an average 10–year CVD risk of 6.3%. Conclusions: Apart from non‐fatal MI s, there was no evidence that intensive glucose‐lowering and multifactorial interventions reduced or increased the risk of cardiovascular and mortality outcomes. Intensive glucose‐lowering and multifactorial interventions are likely to be beneficial in populations with a higher baseline incidence of CV mortality, but there was no evidence of an association with the mean duration of Type 2 diabetes. Multifactorial interventions had a much greater impact on non‐fatal MI and non‐fatal strokes. (PROSPERO registration no.: 42014013860)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Severe hypoglycemia and risks of vascular events and death
Zoungas, S., Patel, A., Chalmers, J., de Galan, B. E., Li, Q., Billot, L., Woodward, M., Ninomiya, T., Neal, B., MacMahon, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003795 · Cited by 1,471
Intensive glucose control and macrovascular outcomes in type 2 diabetes
Turnbull, F. M., Abraira, C., Anderson, R. J., Byington, R. P., Chalmers, J. P., Duckworth, W. C., Evans, G. W., Gerstein, H. C., Holman, R. R., Moritz, T. E., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1470-0 · Cited by 1,189
Boussageon, R., Bejan-Angoulvant, T., Saadatian-Elahi, M., Lafont, S., Bergeonneau, C., Kassai, B., Erpeldinger, S., Wright, J. M., Gueyffier, F., & Cornu, C. (2011) · BMJ · doi:10.1136/bmj.d4169 · Cited by 803
Griffin, S. J., Borch-Johnsen, K., Davies, M. J., Khunti, K., Rutten, G. E., Sandbæk, A., Sharp, S. J., Simmons, R. K., van den Donk, M., Wareham, N. J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60698-3 · Cited by 462
Self-citationRiddle, M. C., Ambrosius, W. T., Brillon, D. J., Buse, J. B., Byington, R. P., Cohen, R. M., Goff, D. C., Malozowski, S., Margolis, K. L., Probstfield, J. L., et al. (2010) · Diabetes Care · doi:10.2337/dc09-1278 · Cited by 406
Udell, J. A., Cavender, M. A., Bhatt, D. L., Chatterjee, S., Farkouh, M. E., & Scirica, B. M. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00044-3 · Cited by 254
Duckworth, W. C., Abraira, C., Moritz, T. E., Davis, S. N., Emanuele, N., Goldman, S., Hayward, R., Huang, G. D., Marks, J. B., Reaven, P. D., et al. (2011) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2011.10.003 · Cited by 152
Cited by
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
Self-citationKDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Self-citationHankey, G. J. (2017) · The Lancet · doi:10.1016/s0140-6736(16)30962-x · Cited by 1,226
The Lancet Commission on diabetes: using data to transform diabetes care and patient lives
Chan, J. C. N., Lim, L.-L., Wareham, N. J., Shaw, J. E., Orchard, T. J., Zhang, P., Lau, E. S. H., Eliasson, B., Kong, A. P. S., Ezzati, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32374-6 · Cited by 793
Self-citationAl-Salameh, A., Chanson, P., Bucher, S., Ringa, V., & Becquemont, L. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.08.007 · Cited by 77
Metadata
- Authors
- Seidu, S., Achana, F. A., Gray, L. J., Davies, M. J., & Khunti, K.
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2015-09-08
- Volume
- 33
- Issue
- 3
- Pages
- 280-289
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W2145191561
- Cited by
- 43
- References
- 9
- FWCI
- 3.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of glucose‐lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta‐analysis of randomized control trials. https://app.cochat.ai/papers/10.1111/dme.12885
- The paper
- Seidu, S., Achana, F. A., Gray, L. J., Davies, M. J., & Khunti, K. (2016). Effects of glucose‐lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta‐analysis of randomized control trials. Diabetic Medicine. https://doi.org/10.1111/dme.12885
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.